MX2019006517A - Moduladores de ror gamma (rorv). - Google Patents

Moduladores de ror gamma (rorv).

Info

Publication number
MX2019006517A
MX2019006517A MX2019006517A MX2019006517A MX2019006517A MX 2019006517 A MX2019006517 A MX 2019006517A MX 2019006517 A MX2019006517 A MX 2019006517A MX 2019006517 A MX2019006517 A MX 2019006517A MX 2019006517 A MX2019006517 A MX 2019006517A
Authority
MX
Mexico
Prior art keywords
rory
modulators
formula
ror gamma
ror
Prior art date
Application number
MX2019006517A
Other languages
English (en)
Inventor
Maria Gerardus Barbara Cals Joseph
Bernardus Nabuurs Sander
Machnik David
François SABUCO Jean-
Original Assignee
Lead Pharma Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lead Pharma Holding Bv filed Critical Lead Pharma Holding Bv
Publication of MX2019006517A publication Critical patent/MX2019006517A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Radiation-Therapy Devices (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud se refiere a compuestos de acuerdo con (Fórmula lA) o (Fórmula IB): (Fórmula lA) (Fórmula IB) o una sal farmacéuticamente aceptable de los mismos. Los compuestos pueden usarse como inhibidores de ROR? y son útiles para el tratamiento de enfermedades mediadas por ROR?.
MX2019006517A 2016-12-05 2017-12-05 Moduladores de ror gamma (rorv). MX2019006517A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16202175 2016-12-05
PCT/EP2017/081489 WO2018104288A1 (en) 2016-12-05 2017-12-05 ROR gamma (RORy) modulators

Publications (1)

Publication Number Publication Date
MX2019006517A true MX2019006517A (es) 2019-08-22

Family

ID=57482312

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006517A MX2019006517A (es) 2016-12-05 2017-12-05 Moduladores de ror gamma (rorv).

Country Status (34)

Country Link
US (3) US10196350B2 (es)
EP (1) EP3548016B1 (es)
JP (1) JP6955563B2 (es)
KR (1) KR102554776B1 (es)
CN (1) CN110352054B (es)
AR (1) AR110481A1 (es)
AU (1) AU2017373593B2 (es)
BR (1) BR112019010461A2 (es)
CA (1) CA3045946A1 (es)
CL (1) CL2019001406A1 (es)
CO (1) CO2019007186A2 (es)
CR (1) CR20190321A (es)
DK (1) DK3548016T3 (es)
DO (1) DOP2019000119A (es)
EA (1) EA201991373A1 (es)
EC (1) ECSP19047767A (es)
ES (1) ES2830759T3 (es)
HU (1) HUE052470T2 (es)
IL (1) IL267045B (es)
LT (1) LT3548016T (es)
MA (1) MA46965B1 (es)
MX (1) MX2019006517A (es)
MY (1) MY194174A (es)
NZ (1) NZ755105A (es)
PE (1) PE20191545A1 (es)
PH (1) PH12019501231A1 (es)
PL (1) PL3548016T3 (es)
PT (1) PT3548016T (es)
RS (1) RS60964B1 (es)
TW (1) TWI705958B (es)
UA (1) UA123751C2 (es)
UY (1) UY37507A (es)
WO (1) WO2018104288A1 (es)
ZA (1) ZA201902288B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101009A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
AR110481A1 (es) 2016-12-05 2019-04-03 Lead Pharma Holding Bv MODULADORES DE ROR g (RORg)
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505080A (ja) 2004-07-01 2008-02-21 ニューヨーク ユニバーシティー ＲＯＲγｔ機能の調節のための組成物および方法
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2013029338A1 (en) 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
AU2013259624B2 (en) 2012-05-08 2017-10-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
WO2013171729A2 (en) * 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
US9359315B2 (en) 2013-09-10 2016-06-07 Arrien Pharmaceuticals Llc Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
HUE043258T2 (hu) * 2013-12-05 2019-08-28 Lead Pharma Holding Bv ROR gamma (RORy) modulátorok
TW201605797A (zh) 2013-12-10 2016-02-16 葛蘭馬克製藥公司 作為ror伽馬調節物的雙環雜芳基化合物
CN105829316B (zh) 2013-12-19 2019-01-08 默克专利股份公司 作为RORγ抑制剂的四氢-四唑并[1，5-a]吡嗪
WO2015101928A1 (en) 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Fused thiophene and thiazole derivatives as ror gamma modulators
MX371017B (es) 2014-02-03 2020-01-13 Vitae Pharmaceuticals Llc Inhibidores de dihidropirrolopiridina de receptor huerfano relacionado-gamma.
WO2015145371A1 (en) * 2014-03-27 2015-10-01 Piramal Enterprises Limited Ror-gamma modulators and uses thereof
PT3131902T (pt) 2014-04-14 2019-09-17 Boehringer Ingelheim Int Compostos como moduladores de ror gama
PT3294713T (pt) 2015-05-15 2021-05-24 Aurigene Discovery Tech Ltd Compostos de tetra-hidroquinolinona como moduladores ror gama
EP3101005A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101007A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101006A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101009A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101008A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
MX2018001464A (es) 2015-08-03 2018-05-28 Glenmark Pharmaceuticals Sa Compuestos nuevos como moduladores de ror gamma.
WO2017213137A1 (ja) 2016-06-09 2017-12-14 アグロカネショウ株式会社 新規化合物およびこれを有効成分とする農園芸用薬剤
AR110481A1 (es) 2016-12-05 2019-04-03 Lead Pharma Holding Bv MODULADORES DE ROR g (RORg)
JP2019026575A (ja) 2017-07-27 2019-02-21 アグロカネショウ株式会社 新規化合物およびこれを有効成分とする農園芸用殺菌剤

Also Published As

Publication number Publication date
IL267045A (en) 2019-07-31
US10196350B2 (en) 2019-02-05
ES2830759T3 (es) 2021-06-04
CL2019001406A1 (es) 2019-10-18
TWI705958B (zh) 2020-10-01
CN110352054A (zh) 2019-10-18
US11299456B2 (en) 2022-04-12
BR112019010461A2 (pt) 2019-09-10
PL3548016T3 (pl) 2021-02-08
ECSP19047767A (es) 2019-08-30
PE20191545A1 (es) 2019-10-24
TW201835038A (zh) 2018-10-01
DOP2019000119A (es) 2019-09-30
CR20190321A (es) 2019-09-11
JP6955563B2 (ja) 2021-10-27
UY37507A (es) 2018-06-29
MY194174A (en) 2022-11-17
DK3548016T3 (da) 2020-11-16
JP2020500886A (ja) 2020-01-16
US20200190028A1 (en) 2020-06-18
UA123751C2 (uk) 2021-05-26
LT3548016T (lt) 2021-01-11
CN110352054B (zh) 2022-11-01
EP3548016B1 (en) 2020-09-02
US20190119204A1 (en) 2019-04-25
IL267045B (en) 2021-07-29
EP3548016A1 (en) 2019-10-09
CA3045946A1 (en) 2018-06-14
MA46965B1 (fr) 2020-12-31
EA201991373A1 (ru) 2019-11-29
KR20190096365A (ko) 2019-08-19
CO2019007186A2 (es) 2019-08-20
PT3548016T (pt) 2020-10-08
PH12019501231A1 (en) 2019-09-23
NZ755105A (en) 2023-01-27
RS60964B1 (sr) 2020-11-30
US20180162808A1 (en) 2018-06-14
AU2017373593B2 (en) 2022-04-07
WO2018104288A1 (en) 2018-06-14
AR110481A1 (es) 2019-04-03
AU2017373593A1 (en) 2019-07-25
KR102554776B1 (ko) 2023-07-11
HUE052470T2 (hu) 2022-02-28
ZA201902288B (en) 2020-10-28

Similar Documents

Publication Publication Date Title
MX2017015741A (es) Moduladores de ror gamma (ror?).
MX2017015739A (es) Moduladores de ror gamma (ror?).
MX2017015740A (es) Moduladores de ror gamma (ror?).
MX2017015737A (es) Moduladores de ror gamma (ror?).
PH12020500252A1 (en) Compounds as modulators of ror gamma
PH12016502355B1 (en) Pharmaceutical composition
MA40171A (fr) Dérivés d'azamophinan et leur utilisation
PH12018501237A1 (en) Isoindole compounds
PH12017500737A1 (en) Kcnq2-5 channel activator
PH12016502352A1 (en) Pharmaceutical composition
MX2018007074A (es) Moduladores de canales de kv3 para tratar dolor.
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
AU2015299431B2 (en) Pyrrolidinone derivatives as metAP-2 inhibitors
TW201613578A (en) Pharmaceutical combinations
PH12019501231A1 (en) ROR GAMMA (RORy) MODULATORS
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
AU2015292632B2 (en) Aldosterone synthase inhibitors
MX2014013758A (es) Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
AU2016248387A8 (en) Preparation and use of kinase inhibitor
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
IL283295A (en) gli1 inhibitors as therapeutic agents
NZ728036A (en) Pharmaceutical compositions comprising antibacterial agents